Company: LGNZZ
Filing Date: 2025-04-17
Form Type: 8-K
Source: 0000886163-25-000020
Chunk: 1

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-04-17
Form: 8-K
Item: Item 9.01
Chunk 1
---
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

  Exhibit No.               Description                                                                                                                                         
         99.1               Press release dated April 17, 2025.                                                                                                                 
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                   104                                               Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.  

Forward-Looking Statements

This report contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties and reflect Ligand’s judgment as of the date of this report. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements.

All statements contained herein, other than statements of historical fact, could be deemed to be forward-looking statements. In some instances, forward-looking statements can be identified by the use of forward-looking words such as “believes,” “expects,” “may,” “will,” “plan,” “intends,” “estimates,” “would,” “continue,” “seeks,” “pro forma,” or “anticipates,” or other similar words (including their use in the negative), or by discussions of the risks and uncertainties associated with future matters, such as those related to our future results of operations and financial position; Ligand’s future royalty payments due under its existing royalty agreements; product development and product regulatory filings and approvals, and the timing thereof; Ligand or its partners may not be able to protect their intellectual property, and patents covering certain products and technologies may be challenged or invalidated which could expose Ligand to significant liabilities and have a material adverse effect on the company; the ability of the parties to consummate the Transaction on a timely basis or at all; the satisfaction of the conditions precedent to consummation of the Transaction; business disruption of Ligand or Pelthos prior to or following the Transaction; the effect of the announcement of the Transaction on the ability of Ligand or Pelthos to retain and hire key personnel and maintain relationships with suppliers and others with whom Ligand or Pelthos do business; the outcome of any legal proceedings related to the Transaction; the impact